Tyr694
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr694  -  STAT5A (mouse)

Site Information
LAKAVDGyVKPQIKQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447767
Associated spectra:  1 CST

In vivo Characterization
Methods used to characterize site in vivo:
flow cytometry ( 1 , 7 , 75 ) , immunoprecipitation ( 7 ) , mass spectrometry ( 2 , 4 , 8 , 9 , 10 , 11 , 16 , 18 , 22 , 23 , 27 , 28 , 29 , 30 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 60 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 76 , 77 , 79 , 80 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 120 , 122 , 123 , 124 , 125 , 126 , 127 , 129 , 130 , 131 , 132 , 133 ) , mutation of modification site ( 1 , 128 , 140 , 142 , 144 ) , phospho-antibody ( 1 , 3 , 5 , 7 , 8 , 13 , 15 , 17 , 21 , 24 , 26 , 27 , 31 , 32 , 45 , 59 , 61 , 75 , 78 , 81 , 82 , 92 , 115 , 119 , 121 , 128 , 134 , 135 , 137 , 138 , 139 , 140 , 142 , 143 ) , western blotting ( 3 , 5 , 7 , 8 , 13 , 15 , 17 , 21 , 24 , 26 , 32 , 45 , 59 , 61 , 75 , 78 , 81 , 82 , 92 , 115 , 128 , 135 , 139 , 140 )
Disease tissue studied:
anthrax infection ( 16 ) , leukemia ( 7 , 59 , 62 , 63 , 64 , 65 , 66 , 129 , 130 , 131 , 132 , 133 , 140 ) , acute myelogenous leukemia ( 140 ) , acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b) ( 59 ) , chronic myelogenous leukemia ( 7 , 62 , 63 , 64 , 65 , 66 , 129 , 130 , 131 , 132 , 133 ) , lung cancer ( 55 , 56 , 57 , 82 ) , non-small cell lung cancer ( 22 ) , lymphoma ( 21 ) , T cell lymphoma ( 21 ) , Turner-like syndrome ( 36 , 37 )
Relevant cell line - cell type - tissue:
'3T3-L1, differentiated' (adipocyte) ( 4 , 9 ) , 'fat, brown' ( 18 ) , 'muscle, skeletal' ( 32 ) , 10T1/2 (fibroblast) ( 43 , 44 , 46 ) , 293 (epithelial) ( 5 , 115 ) , 293T (epithelial) ( 143 ) , 32D (myeloid) ( 15 , 135 ) , 32D (myeloid) [IRS1 (mouse)] ( 121 ) , 32Dcl3 (myeloid) ( 27 ) , 32Dcl3 (myeloid) [FLT3 (mouse), transfection, chimera with human FLT3-ITD mutant (corresponding to wild type P36888 ~aa 525-695 ETILLNS...IFEYCC)] ( 27 ) , 3T3 (fibroblast) ( 92 , 122 ) , 3T3 (fibroblast) [Pyk2 (human), transfection, stable Pyk2 (v5-His tagged) transfection, in RU-486 (mifepristone)-inducible expression system] ( 23 ) , 3T3 (fibroblast) [Src (human)] ( 82 ) , AS-E2 (myeloid) ( 140 ) , B lymphocyte [ECM1 (mouse), homozygous knockout] ( 17 ) , B lymphocyte-spleen ( 5 ) , BaF3 ('B lymphocyte, precursor') ( 13 , 21 , 24 , 26 , 30 , 59 , 62 , 63 , 64 , 65 , 66 , 75 , 81 , 86 , 87 , 88 , 89 , 90 , 91 , 93 , 94 , 95 , 96 , 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 116 , 117 , 118 , 120 , 123 , 124 , 125 , 126 , 127 , 129 , 130 , 131 , 132 , 133 , 135 , 143 ) , BaF3 ('B lymphocyte, precursor') [EGFR (human)] ( 82 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 2 ) , bone marrow ( 3 , 21 , 81 ) , COS (fibroblast) ( 134 , 144 ) , CTL-EN (T lymphocyte) ( 61 ) , DA-3 (breast cell) ( 143 ) , EL-4 (T lymphocyte) ( 21 ) , erythroblast ( 59 ) , erythroblast-spleen ( 143 ) , FDCP-1 (myeloid) ( 119 ) , fibroblast-lung ( 92 ) , FL5.12 (lymphoid) ( 121 ) , HC11 (epithelial) ( 31 , 137 , 138 ) , HCD 57 (erythroid) ( 143 ) , heart ( 34 , 35 , 36 , 37 , 38 , 58 , 76 ) , HEL (erythroid) ( 59 ) , hepatocyte-liver [BCR-ABL1 (human), transgenic] ( 7 ) , K562 (erythroid) [BCR-ABL1 (human), transgenic] ( 7 ) , kidney ( 18 ) , KU812 (myeloid) [BCR-ABL1 (human), transgenic] ( 7 ) , liver ( 18 , 60 , 71 , 72 , 73 , 74 , 77 , 79 ) , liver [Akt2 (mouse), homozygous knockout] ( 67 , 68 , 69 , 70 ) , lung ( 22 , 80 ) , lung [EGFR (mouse), transgenic, mutant] ( 56 ) , lung [EGFR (mouse), transgenic] ( 55 ) , lung [HRas (mouse), transgenic] ( 57 ) , lymphocyte-spleen ( 5 ) , MC/9 (mast) ( 135 ) , MEF (fibroblast) ( 32 , 33 , 139 ) , myeloid-bone marrow ( 59 ) , myocyte-heart ( 78 ) , Sf21 ( 142 ) , spleen ( 16 , 21 , 29 ) , splenocyte ( 75 ) , SYF (fibroblast) [Src (mouse), transfection] ( 10 ) , T lymphocyte ( 1 ) , T lymphocyte [ECM1 (mouse), homozygous knockout, KO] ( 17 ) , T lymphocyte-blood ( 45 ) , T lymphocyte-thymus ( 139 ) , thymus ( 28 ) , TonB [BCR-ABL1 (human), transgenic] ( 8 )

Upstream Regulation
Regulatory protein:
BCR-ABL1 (human) ( 8 ) , DUSP4 (human) ( 5 ) , ECM1 (mouse) ( 17 ) , EPOR (mouse) ( 24 ) , FLT3 (mouse) ( 27 ) , GAB2 (mouse) ( 3 ) , ITGA9 (human) ( 81 ) , JAK2 (human) ( 59 ) , LYN (mouse) ( 19 ) , MRas (human) ( 135 ) , PLCB3 (mouse) ( 19 ) , RHOA (mouse) ( 136 ) , STAT3 (mouse) ( 78 )
Putative in vivo kinases:
Btk (human) ( 142 ) , JAK2 (mouse) ( 136 )
Kinases, in vitro:
Btk (mouse) ( 142 )
Treatments:
AG490 ( 8 ) , anti-IL-2 ( 17 ) , brefeldin_A ( 27 ) , bromocriptine ( 78 ) , cardiotropin-1 ( 92 ) , CXCL5 ( 32 ) , EGF ( 31 , 134 ) , Epo ( 24 , 26 , 59 , 140 , 143 ) , exoenzyme_C3 ( 128 ) , fedratinib ( 59 ) , G-CSF ( 81 ) , gefitinib ( 82 ) , GH ( 139 ) , GM-CSF ( 61 ) , IFN-alpha ( 143 ) , IFN-beta ( 5 ) , IL-11 ( 92 ) , IL-2 ( 17 , 45 , 75 , 139 ) , IL-21 ( 75 ) , IL-3 ( 8 , 13 , 19 , 21 , 59 , 119 , 141 , 143 ) , IL-3_withdrawal ( 8 ) , IL-6 ( 92 ) , IL-7 ( 45 ) , IL-9 ( 135 ) , imatinib ( 7 , 8 , 121 ) , insulin ( 9 ) , JAK_inhibitor_I ( 13 , 25 ) , LIF ( 92 ) , LPA ( 136 ) , LY294002 ( 141 ) , MPA ( 121 ) , oncostatin_M ( 92 ) , PGE2 ( 140 ) , PKC412 ( 27 ) , pregnancy ( 78 ) , PRL ( 31 , 78 , 138 ) , staurosporine ( 139 ) , TPO ( 25 ) , tunicamycin ( 27 )

Downstream Regulation
Effects of modification on STAT5A:
activity, induced ( 24 , 136 , 140 , 144 )
Effects of modification on biological processes:
cell growth, altered ( 24 ) , transcription, altered ( 24 , 142 , 144 ) , transcription, induced ( 5 )
Induce interaction with:
DNA ( 136 )

References 

1

Gonnord P, et al. (2018) A hierarchy of affinities between cytokine receptors and the common gamma chain leads to pathway cross-talk. Sci Signal 11
29615515   Curated Info

2

Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia
28852199   Curated Info

3

Gu S, et al. (2016) Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Blood 127, 1803-13
26773044   Curated Info

4

Parker BL, et al. (2015) Targeted phosphoproteomics of insulin signaling using data-independent acquisition mass spectrometry. Sci Signal 8, rs6
26060331   Curated Info

5

Hsiao WY, et al. (2015) Dual-Specificity Phosphatase 4 Regulates STAT5 Protein Stability and Helper T Cell Polarization. PLoS One 10, e0145880
26710253   Curated Info

6

Patton DT, Plumb AW, Abraham N (2014) The survival and differentiation of pro-B and pre-B cells in the bone marrow is dependent on IL-7Rα Tyr449. J Immunol 193, 3446-55
25143441   Curated Info

7

Berger A, et al. (2014) PAK-dependent STAT5 serine phosphorylation is required for BCR-ABL-induced leukemogenesis. Leukemia 28, 629-41
24263804   Curated Info

8

Schaller-Schönitz M, et al. (2014) BCR-ABL Affects STAT5A and STAT5B Differentially. PLoS One 9, e97243
24836440   Curated Info

9

Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20
23684622   Curated Info

10

Ferrando IM, et al. (2012) Identification of targets of c-Src tyrosine kinase by chemical complementation and phosphoproteomics. Mol Cell Proteomics 11, 355-69
22499769   Curated Info

11

Ren H (2011) CST Curation Set: 12905; Year: 2011; Biosample/Treatment: /untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Grebien F, et al. (2011) Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis. Cell 147, 306-19
22000011   Curated Info

13

Jäkel H, Weinl C, Hengst L (2011) Phosphorylation of p27Kip1 by JAK2 directly links cytokine receptor signaling to cell cycle control. Oncogene 30, 3502-12
21423214   Curated Info

14

Zheng Y, et al. (2011) A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. Blood 118, 156-66
21527517   Curated Info

15

Arora D, et al. (2011) Protein-tyrosine phosphatase DEP-1 controls receptor tyrosine kinase FLT3 signaling. J Biol Chem 286, 10918-29
21262971   Curated Info

16

Manes NP, et al. (2011) Discovery of mouse spleen signaling responses to anthrax using label-free quantitative phosphoproteomics via mass spectrometry. Mol Cell Proteomics 10, M110.000927
21189417   Curated Info

17

Li Z, et al. (2011) ECM1 controls T(H)2 cell egress from lymph nodes through re-expression of S1P(1). Nat Immunol 12, 178-85
21217760   Curated Info

18

Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89
21183079   Curated Info

19

Xiao W, et al. (2010) Lyn- and PLC-beta3-dependent regulation of SHP-1 phosphorylation controls Stat5 activity and myelomonocytic leukemia-like disease. Blood 116, 6003-13
20858858   Curated Info

20

Titz B, et al. (2010) The proximal signaling network of the BCR-ABL1 oncogene shows a modular organization. Oncogene 29, 5895-910
20697350   Curated Info

21

Friedbichler K, et al. (2010) Stat5a serine 725 and 779 phosphorylation is a prerequisite for hematopoietic transformation. Blood 116, 1548-58
20508164   Curated Info

22

Carretero J, et al. (2010) Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell 17, 547-59
20541700   Curated Info

23

Bonnette PC, et al. (2010) Phosphoproteomic characterization of PYK2 signaling pathways involved in osteogenesis. J Proteomics 73, 1306-20
20116462   Curated Info

24

Funakoshi-Tago M, et al. (2010) STAT5 activation is critical for the transformation mediated by myeloproliferative disorder-associated JAK2 V617F mutant. J Biol Chem 285, 5296-307
20028972   Curated Info

25

Saur SJ, et al. (2010) Ubiquitination and degradation of the thrombopoietin receptor c-Mpl. Blood 115, 1254-63
19880496   Curated Info

26

Liron T, Nahari T, Souroujon MC, Neumann D (2010) Insertion of an NPVY sequence into the cytosolic domain of the erythropoietin receptor selectively affects erythropoietin-mediated signalling and function. Biochem J 427, 305-12
20136632   Curated Info

27

Choudhary C, et al. (2009) Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes. Mol Cell 36, 326-39
19854140   Curated Info

28

Guo A (2009) CST Curation Set: 7710; Year: 2009; Biosample/Treatment: tissue, thymus/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

29

Guo A (2009) CST Curation Set: 7708; Year: 2009; Biosample/Treatment: tissue, spleen/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

30

Moritz A (2009) CST Curation Set: 7223; Year: 2009; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

31

Haines E, et al. (2009) Tyrosine phosphorylation of Grb2: role in prolactin/epidermal growth factor cross talk in mammary epithelial cell growth and differentiation. Mol Cell Biol 29, 2505-20
19273609   Curated Info

32

Chavey C, et al. (2009) CXC ligand 5 is an adipose-tissue derived factor that links obesity to insulin resistance. Cell Metab 9, 339-49
19356715   Curated Info

33

Li Y (2009) CST Curation Set: 6296; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

34

Stokes M (2008) CST Curation Set: 5664; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

35

Stokes M (2008) CST Curation Set: 5665; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

36

Stokes M (2008) CST Curation Set: 5666; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

37

Stokes M (2008) CST Curation Set: 5667; Year: 2008; Biosample/Treatment: cell line, Noonan Syndrome mouse heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

38

Stokes M (2008) CST Curation Set: 4847; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

39

Rikova K (2008) CST Curation Set: 4790; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KT-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

40

Rikova K (2008) CST Curation Set: 4771; Year: 2008; Biosample/Treatment: cell line, Dana Farber-KTL-1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

41

Rikova K (2008) CST Curation Set: 4837; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L1/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

42

Rikova K (2008) CST Curation Set: 4838; Year: 2008; Biosample/Treatment: cell line, Dana Farber-L2/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

43

Li Y (2008) CST Curation Set: 4544; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

44

Li Y (2008) CST Curation Set: 4543; Year: 2008; Biosample/Treatment: cell line, 10T1/2/FGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

45

Shi M, Lin TH, Appell KC, Berg LJ (2008) Janus-kinase-3-dependent signals induce chromatin remodeling at the Ifng locus during T helper 1 cell differentiation. Immunity 28, 763-73
18549798   Curated Info

46

Li Y (2008) CST Curation Set: 4541; Year: 2008; Biosample/Treatment: cell line, 10T1/2/control; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

47

Rikova K (2008) CST Curation Set: 4476; Year: 2008; Biosample/Treatment: cell line, MD Ander 1158(393P)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

48

Rikova K (2008) CST Curation Set: 4481; Year: 2008; Biosample/Treatment: cell line, MD Ander a0859/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

49

Rikova K (2008) CST Curation Set: 4477; Year: 2008; Biosample/Treatment: cell line, MD Ander 1154/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

50

Rikova K (2008) CST Curation Set: 4478; Year: 2008; Biosample/Treatment: cell line, MD Ander 0895/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

51

Rikova K (2008) CST Curation Set: 4479; Year: 2008; Biosample/Treatment: cell line, MD Ander 1202(344SQ)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

52

Rikova K (2008) CST Curation Set: 4480; Year: 2008; Biosample/Treatment: cell line, MD Ander 1249/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

53

Rikova K (2008) CST Curation Set: 4474; Year: 2008; Biosample/Treatment: cell line, MD Ander 393LN/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

54

Rikova K (2008) CST Curation Set: 4475; Year: 2008; Biosample/Treatment: cell line, MD Ander 1169/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

55

Ren H (2008) CST Curation Set: 4335; Year: 2008; Biosample/Treatment: cell line, EGFR_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

56

Ren H (2008) CST Curation Set: 4336; Year: 2008; Biosample/Treatment: cell line, EGFR_M/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

57

Ren H (2008) CST Curation Set: 4337; Year: 2008; Biosample/Treatment: cell line, Ras_WT/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

58

Zhou J (2008) CST Curation Set: 4324; Year: 2008; Biosample/Treatment: tissue, heart/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY
Curated Info

59

Wernig G, et al. (2008) Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera. Cancer Cell 13, 311-20
18394554   Curated Info

60

Possemato A (2008) CST Curation Set: 3845; Year: 2008; Biosample/Treatment: tissue, liver/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: RXXp[ST] Antibodies Used to Purify Peptides prior to LCMS: Phospho-Akt Substrate (RXRXXS/T) (110B7) Rabbit mAb Cat#: 9614, PTMScan(R) Phospho-Akt Substrate Motif (RXXS*/T*) Immunoaffinity Beads Cat#: 1978
Curated Info

61

Ramshaw HS, et al. (2007) The Shc-binding site of the {beta}c subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood 110, 3582-90
17638849   Curated Info

62

Gu T (2007) CST Curation Set: 3402; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

63

Gu T (2007) CST Curation Set: 3403; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

64

Gu T (2007) CST Curation Set: 3404; Year: 2007; Biosample/Treatment: cell line, Baf3(MSCV-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

65

Gu T (2007) CST Curation Set: 3406; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

66

Gu T (2007) CST Curation Set: 3407; Year: 2007; Biosample/Treatment: cell line, Baf3(PLXSN-NEO-FLT3/ITD)/IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

67

Guo A (2007) CST Curation Set: 2987; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

68

Guo A (2007) CST Curation Set: 2988; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

69

Guo A (2007) CST Curation Set: 2989; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

70

Guo A (2007) CST Curation Set: 2990; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

71

Guo A (2007) CST Curation Set: 2983; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

72

Guo A (2007) CST Curation Set: 2984; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

73

Guo A (2007) CST Curation Set: 2985; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

74

Guo A (2007) CST Curation Set: 2986; Year: 2007; Biosample/Treatment: tissue, liver/Insulin; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

75

Zeng R, et al. (2007) The molecular basis of IL-21-mediated proliferation. Blood 109, 4135-42
17234735   Curated Info

76

Guo A (2007) CST Curation Set: 2827; Year: 2007; Biosample/Treatment: tissue, heart/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

77

Guo A (2007) CST Curation Set: 2830; Year: 2007; Biosample/Treatment: tissue, liver/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

78

Hilfiker-Kleiner D, et al. (2007) A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 128, 589-600
17289576   Curated Info

79

Villén J, Beausoleil SA, Gerber SA, Gygi SP (2007) Large-scale phosphorylation analysis of mouse liver. Proc Natl Acad Sci U S A 104, 1488-93
17242355   Curated Info

80

Farnsworth C (2006) CST Curation Set: 2094; Year: 2006; Biosample/Treatment: tissue, lung/-; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

81

Chen C, et al. (2006) The Integrin alpha9beta1 contributes to granulopoiesis by enhancing granulocyte colony-stimulating factor receptor signaling. Immunity 25, 895-906
17137800   Curated Info

82

Sharma SV, et al. (2006) A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10, 425-35
17097564   Curated Info

83

Zhou J (2006) CST Curation Set: 1969; Year: 2006; Biosample1/Treatment/Isotope: tissue, brain/untreated/L, Biosample2/Treatment/Isotope: tissue, brain/untreated/H; Disease: -; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: YXp[ST]
Curated Info

84

Gu T (2006) CST Curation Set: 1520; Year: 2006; Biosample/Treatment: cell line, Thom(MPL)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

85

Gu T (2006) CST Curation Set: 1521; Year: 2006; Biosample/Treatment: cell line, Thom(MPL)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

86

Goss V (2006) CST Curation Set: 1402; Year: 2006; Biosample/Treatment: cell line, BaF3/serum starved &'||' IL3 starvation; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

87

Goss V (2006) CST Curation Set: 1403; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

88

Goss V (2006) CST Curation Set: 1404; Year: 2006; Biosample/Treatment: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

89

Goss V (2006) CST Curation Set: 1405; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/none/L, Biosample2/Treatment/Isotope: cell line, BaF3/none/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

90

Goss V (2006) CST Curation Set: 1406; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo/L, Biosample2/Treatment/Isotope: cell line, BaF3/serum starved &'||' IL3 starvation &'||' Tpo/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

91

Goss V (2006) CST Curation Set: 1302; Year: 2006; Biosample/Treatment: cell line, BaF3/serum starved &'||' IL3 starvation; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

92

Fritz DK, et al. (2006) Oncostatin-M up-regulates VCAM-1 and synergizes with IL-4 in eotaxin expression: involvement of STAT6. J Immunol 176, 4352-60
16547273   Curated Info

93

Goss V (2006) CST Curation Set: 1200; Year: 2006; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

94

Goss V (2006) CST Curation Set: 1080; Year: 2006; Biosample1/Treatment/Isotope: cell line, BaF3/none/L, Biosample2/Treatment/Isotope: cell line, BaF3/none/H; Disease: chronic myelogenous leukemia; SILAC: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

95

Gu T (2005) CST Curation Set: 1056; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

96

Gu T (2005) CST Curation Set: 1057; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

97

Gu T (2005) CST Curation Set: 1058; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

98

Gu T (2005) CST Curation Set: 1059; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

99

Gu T (2005) CST Curation Set: 1060; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

100

Goss V (2005) CST Curation Set: 860; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

101

Goss V (2005) CST Curation Set: 861; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

102

Goss V (2005) CST Curation Set: 862; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

103

Goss V (2005) CST Curation Set: 847; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

104

Goss V (2005) CST Curation Set: 848; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

105

Goss V (2005) CST Curation Set: 859; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

106

Gu T (2005) CST Curation Set: 843; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

107

Gu T (2005) CST Curation Set: 844; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

108

Gu T (2005) CST Curation Set: 845; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

109

Gu T (2005) CST Curation Set: 846; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

110

Gu T (2005) CST Curation Set: 894; Year: 2005; Biosample/Treatment: cell line, BaF3/IL3 &'||' IL3 withdrawal; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

111

Goss V (2005) CST Curation Set: 814; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

112

Goss V (2005) CST Curation Set: 813; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

113

Goss V (2005) CST Curation Set: 815; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

114

Goss V (2005) CST Curation Set: 816; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

115

Clark DE, et al. (2005) ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events. J Biol Chem 280, 24175-80
15863494   Curated Info

116

Goss V (2005) CST Curation Set: 698; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

117

Gu T (2005) CST Curation Set: 699; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

118

Gu T (2005) CST Curation Set: 700; Year: 2005; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

119

James C, et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-8
15793561   Curated Info

120

Goss V (2005) CST Curation Set: 670; Year: 2005; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

121

Gu JJ, Santiago L, Mitchell BS (2005) Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing Bcr-Abl. Blood 105, 3270-7
15604220   Curated Info

122

Guo A (2005) CST Curation Set: 630; Year: 2005; Biosample/Treatment: cell line, 3T3/EGF; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

123

Goss V (2004) CST Curation Set: 494; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

124

Goss V (2004) CST Curation Set: 495; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

125

Goss V (2004) CST Curation Set: 496; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

126

Goss V (2004) CST Curation Set: 475; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

127

Goss V (2004) CST Curation Set: 476; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

128

Ling L, Lobie PE (2004) RhoA/ROCK activation by growth hormone abrogates p300/histone deacetylase 6 repression of Stat5-mediated transcription. J Biol Chem 279, 32737-50
15102857   Curated Info

129

Goss V (2004) CST Curation Set: 384; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

130

Goss V (2004) CST Curation Set: 385; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

131

Goss V (2004) CST Curation Set: 386; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

132

Goss V (2004) CST Curation Set: 395; Year: 2004; Biosample/Treatment: cell line, BaF3/serum starved &'||' Tpo; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

133

Goss V (2004) CST Curation Set: 396; Year: 2004; Biosample/Treatment: cell line, BaF3/-; Disease: chronic myelogenous leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

134

Zhang T, Ma J, Cao X (2003) Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling. Biochem J 376, 457-64
14498832   Curated Info

135

Demoulin JB, et al. (2003) MAP kinase activation by interleukin-9 in lymphoid and mast cell lines. Oncogene 22, 1763-70
12660812   Curated Info

136

Benitah SA, Valerón PF, Rui H, Lacal JC (2003) STAT5a activation mediates the epithelial to mesenchymal transition induced by oncogenic RhoA. Mol Biol Cell 14, 40-53
12529425   Curated Info

137

Park DS, et al. (2002) Caveolin-1-deficient mice show accelerated mammary gland development during pregnancy, premature lactation, and hyperactivation of the Jak-2/STAT5a signaling cascade. Mol Biol Cell 13, 3416-30
12388746   Curated Info

138

Chughtai N, Schimchowitsch S, Lebrun JJ, Ali S (2002) Prolactin induces SHP-2 association with Stat5, nuclear translocation, and binding to the beta-casein gene promoter in mammary cells. J Biol Chem 277, 31107-14
12060651   Curated Info

139

ten Hoeve J, et al. (2002) Identification of a nuclear Stat1 protein tyrosine phosphatase. Mol Cell Biol 22, 5662-8
12138178   Curated Info

140

Boer AK, Drayer AL, Rui H, Vellenga E (2002) Prostaglandin-E2 enhances EPO-mediated STAT5 transcriptional activity by serine phosphorylation of CREB. Blood 100, 467-73
12091337   Curated Info

141

Nguyen MH, Ho JM, Beattie BK, Barber DL (2001) TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. J Biol Chem 276, 32704-13
11435425   Curated Info

142

Mahajan S, et al. (2001) Transcription factor STAT5A is a substrate of Bruton's tyrosine kinase in B cells. J Biol Chem 276, 31216-28
11413148   Curated Info

143

Barber DL, et al. (2001) A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation. Blood 97, 2230-7
11290583   Curated Info

144

Beuvink I, et al. (2000) Stat5a serine phosphorylation. Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity. J Biol Chem 275, 10247-55
10744710   Curated Info